ThermoCas9 Cuts Tumor DNA While Sparing Healthy Cells
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- ThermoCas9 — a CRISPR‑associated enzyme discovered by John van der Oost at Wageningen University & Research, can respond to DNA methylation differences.
- Hong Li — a scientist at Van Andel Institute, analyzed ThermoCas9's structure and showed it can distinguish unmethylated from methylated genes.
- The research team — introduced ThermoCas9 into cultured human cells, observing selective DNA cleavage in tumor cells while healthy cells remained intact.
- ThermoCas9’s PAM — includes a methylation site, so methyl groups prevent binding to healthy DNA, acting like a molecular address.
- The study — published in Nature (2026) as the first CRISPR method that uses methylation to target human cancer cells.
- Future work — will aim to cause enough tumor DNA damage to trigger cell death, and the approach may extend to other methylation‑related diseases.
Why it matters: The ability to cut only methylated tumor DNA gives researchers a precise weapon against cancer, potentially sparing patients healthy tissue and reducing treatment toxicity. If successful, it could shift therapeutic design toward epigenetic signatures, benefiting oncology labs and patients while limiting collateral damage to normal cells.
